Control of PTH secretion by the TRPC1 ion channel by Onopiuk, Marta et al.
 
 
University of Birmingham
Control of PTH secretion by the TRPC1 ion channel
Onopiuk, Marta; Eby, Bonnie; Nesin, Vasyl; Ngo, Peter; Lerner, Megan; Gorvin, Caroline M;
Stokes, Victoria J; Thakker, Rajesh V; Brandi, Maria Luisa; Chang, Wenhan; Humphrey, Mary
Beth; Tsiokas, Leonidas; Lau, Kai
DOI:
10.1172/jci.insight.132496
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Onopiuk, M, Eby, B, Nesin, V, Ngo, P, Lerner, M, Gorvin, CM, Stokes, VJ, Thakker, RV, Brandi, ML, Chang, W,
Humphrey, MB, Tsiokas, L & Lau, K 2020, 'Control of PTH secretion by the TRPC1 ion channel', JCI Insight, vol.
5, no. 8, pp. 1-17. https://doi.org/10.1172/jci.insight.132496
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 14. Jun. 2020
Control of PTH secretion by the TRPC1 ion channel
Marta Onopiuk, … , Leonidas Tsiokas, Kai Lau
JCI Insight. 2020;5(8):e132496. https://doi.org/10.1172/jci.insight.132496.
  
Graphical abstract
Research Article Cell biology Endocrinology
Find the latest version:
https://jci.me/132496/pdf
1insight.jci.org   https://doi.org/10.1172/jci.insight.132496
R E S E A R C H  A R T I C L E
Authorship note: MO and BE 
contributed equally to this work.
Conflict of interest: The authors have 
declared that no conflict of interest 
exists.
Copyright: © 2020, Onopiuk et 
al. This is an open access article 
published under the terms of the 
Creative Commons Attribution 4.0 
International License
Submitted: August 8, 2019 
Accepted: March 16, 2020 
Published: April 23, 2020.
Reference information: JCI Insight. 
2020;5(8):e132496. 
https://doi.org/10.1172/jci.
insight.132496.
Control of PTH secretion by the TRPC1 ion 
channel
Marta Onopiuk,1 Bonnie Eby,2 Vasyl Nesin,1 Peter Ngo,1 Megan Lerner,3 Caroline M. Gorvin,4  
Victoria J. Stokes,4 Rajesh V. Thakker,4 Maria Luisa Brandi,5 Wenhan Chang,6  
Mary Beth Humphrey,7,8 Leonidas Tsiokas,1 and Kai Lau2,8
1Department of Cell Biology and 2Department of Medicine, Division of Nephrology, University of Oklahoma Health 
Sciences Center, Oklahoma City, Oklahoma, USA. 3Department of Surgery, Oklahoma City, Oklahoma, USA. 4Academic 
Endocrine Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom. 5Department of 
Biomedicals Sperimentals and Clinicals Sciences, Università degli Studi di Firenze and Fondazione FIRMO, Florence, Italy. 
6Endocrinology and Metabolism, Department of Medicine, UCSF, San Francisco, California, USA. 7Department of Medicine, 
Division of Rheumatology, Immunology, and Allergy, University of Oklahoma Health Sciences Center, Oklahoma City, 
Oklahoma, USA. 8Department of Veterans Affairs, Oklahoma City, Oklahoma, USA.
Introduction
Parathyroid hormone (PTH) is a critical hormone for Ca2+ homeostasis. In normal conditions, levels of  
PTH are tightly controlled by serum Ca2+ via a negative feedback mechanism in which high serum Ca2+ 
levels suppress the production and/or secretion of  PTH from the parathyroid gland (PTG). This feedback 
mechanism prevents the development of  hypercalcemia or hypocalcemia. In primary hyperparathyroidism 
often resulting from PTG adenomas, abnormally high levels of  PTH result in hypercalcemia, whereas in 
secondary hyperparathyroidism, frequently seen in renal failure, elevated PTH levels are actually associ-
ated with hypocalcemia. Patients with naturally occurring mutations in the gene encoding the Ca2+-sens-
ing receptor (CaSR) (1, 2), GNA11 encoding G protein subunit α 11 (Gα11) (3), or AP2S1 encoding the 
clathrin-associated adaptor protein-2 σ subunit 2 (AP2σ2) (4) develop familial hypocalciuric hypercalcemia 
(FHH), characterized by hypercalcemia and hypocalciuria and, in some cases, by inappropriately elevated 
levels (5). Proteins encoded by the FHH-associated genes function in a linear signaling pathway within the 
PTG to suppress production and secretion of  PTH in response to hypercalcemia. However, an outstanding 
question has been how hypercalcemia causes the suppression of  PTH production and secretion. It has been 
suggested that a critical step involves a transient rise in intracellular Ca2+ concentration in response to high 
serum Ca2+ levels (6, 7). In contrast to most endocrine systems, where an increase in intracellular Ca2+ con-
centration triggers exocytosis and hormonal release, the PTG is unique in that an increase in intracellular 
Ca2+ concentration instead suppresses PTH release (7) The molecular identity of  the ion channels mediat-
ing this transient increase in intracellular Ca2+ concentration driving the suppression of  PTH release has 
been unknown. Therefore, identification of  these channels and the mechanisms underlying CaSR-induced 
Familial hypocalciuric hypercalcemia (FHH) is a genetic condition associated with hypocalciuria, 
hypercalcemia, and, in some cases, inappropriately high levels of circulating parathyroid hormone 
(PTH). FHH is associated with inactivating mutations in the gene encoding the Ca2+-sensing receptor 
(CaSR), a GPCR, and GNA11 encoding G protein subunit α 11 (Gα11), implicating defective GPCR 
signaling as the root pathophysiology for FHH. However, the downstream mechanism by which 
CaSR activation inhibits PTH production/secretion is incompletely understood. Here, we show 
that mice lacking the transient receptor potential canonical channel 1 (TRPC1) develop chronic 
hypercalcemia, hypocalciuria, and elevated PTH levels, mimicking human FHH. Ex vivo and in 
vitro studies revealed that TRPC1 serves a necessary and sufficient mediator to suppress PTH 
secretion from parathyroid glands (PTGs) downstream of CaSR in response to high extracellular Ca2+ 
concentration. Gα11 physically interacted with both the N- and C-termini of TRPC1 and enhanced 
CaSR-induced TRPC1 activity in transfected cells. These data identify TRPC1-mediated Ca2+ 
signaling as an essential component of the cellular apparatus controlling PTH secretion in the PTG 
downstream of CaSR.
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Ca2+ signaling suppression of  PTH secretion are of  paramount importance in understanding and treating 
pathological conditions resulting from abnormal PTH levels.
CaSR is coupled to 3 subclasses of  G proteins, Gα11/αq, Gαi/o, and Gα12/13 (8, 9). The identification 
of  GNA11 as an FHH-associated gene and further functional and genetic studies on Gα11 indicate that the 
coupling of  CaSR to Gα11 may be directly linked to the suppression of  PTH production and/or secretion. 
Activation of  Gα11/αq-coupled CaSR leads to the generation of  inositol trisphosphate (IP3), which triggers 
Ca2+ release from ER and stimulation of  Ca2+ influx from the extracellular fluid mediated by store- and/or 
receptor-operated Ca2+ entry (SOCE and/or ROCE) channels, localized at the plasma membrane. SOCE 
channels are defined as the channels activated exclusively via the depletion of  the intracellular Ca2+ stores 
following the activation of  any pathway that involves the generation of  IP3 as a second messenger and involve 
the ER Ca2+ sensor, stromal interaction molecule 1 (STIM1), and the pore-forming subunit, Orai1 (10). ROCE 
channels are activated via intermediaries generated during the activation of  cell surface receptors, and nearly 
all of  the 28 known TRP channels can function as ROCE channels, depending on cell and tissue contexts (11, 
12). Therefore, theoretically both SOCE and ROCE channels can be activated following the stimulation of  the 
CaSR. Transient receptor potential canonical channel 1 (TRPC1) belongs to the canonical subgroup of  TRP 
channels and has been implicated in both SOCE and ROCE (13). TRPC1 can be activated by CaSR in rabbit 
mesenteric arteries (14), colonic epithelial (15, 16), endothelial (17), and breast cancer cells (18), making it an 
ideal candidate for mediating the suppression of  PTH secretion downstream of CaSR in the PTG.
Using a combination of  in vivo, ex vivo, and in vitro approaches, our studies show that TRPC1 func-
tions downstream of  CaSR in the suppression of  PTH secretion and that Trpc1-null mice show an FHH-
like phenotype. However, its mechanism of  activation does not involve store depletion but instead involves 
a protein-protein interaction with Gα11, a protein directly coupled to CaSR and genetically implicated in 
FHH. Thus, our study identifies TRPC1 as one of  the ion channels mediating the mechanism by which 
high Ca2+ serum levels suppress PTH secretion.
Results
Trpc1–/– mice develop FHH. Global Trpc1–/– mice have been described previously (19). Homeostatic serum 
Ca2+ levels were significantly higher in male and female Trpc1–/– mice at 7 months of  age (Figure 1A). 
Hypercalcemia was observed at early as 3.5 months and persisted up to 21.5 months in age-matched null 
littermate males (11.31 ± 0.28 mg/dl in Trpc1–/– vs. 9.92 ± 0.41 mg/dl in Trpc1+/+, P < 0.05) (Supple-
mental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/jci.
insight.132496DS1). Trpc1+/- male mice exhibited significant hypercalcemia (Supplemental Figure 1B), 
suggesting that heterozygous deletion of  Trpc1 was sufficient to produce a hypercalcemic phenotype. PTH 
levels were significantly higher in 7-month-old homozygous mutant males and inappropriately high in 
7-month-old homozygous mutant females (because they were not suppressed by hypercalcemia as expected 
in normal physiology) (Figure 1B). Inappropriately high PTH levels were observed in younger and older 
mice (Supplemental Figure 1C). Hypercalcemia was present in either fasted in Trpc1–/– mutant male or 
female mice (10 hours prior to blood collection) or animals allowed to feed ad libitum, arguing against 
increased gut Ca2+ absorption as the mechanism for the hypercalcemia in mice lacking Trpc1 (Supplemental 
Figure 1D). Despite hypercalcemia, 24-hour urine Ca2+ excretion (Figure 1C), renal Ca2+ clearance (Fig-
ure 1D), and the urine Ca2+/creatinine ratio were all reduced in 7-month-old Trpc1–/– males and females 
(Figure 1E). Reduced urine Ca2+ clearance persisted up to 21.5 months (5.8 ± 3.4 μl/min in Trpc1–/– males 
vs. 29.3 ± 7.9 μl/min in Trpc1+/+ males). Serum Mg2+, renal Mg2+ clearance, urine Mg2+ excretion, and the 
24-hour urine Mg2+/creatinine ratio were unaffected by deletion of  Trpc1 (Table 1). These data indicate 
that Trpc1–/– mice are hypocalciuric and that, overall, they show the classic triad of  FHH of  hypocalciuria, 
hypercalcemia, and significantly elevated or inappropriately high levels of  circulating PTH.
To evaluate if  these phenotypes were secondary to renal disease and/or disorders of  vitamin D metab-
olism, we measured serum levels of  1,25 (OH)2 vitamin D, creatinine, and calcitonin. 1,25 (OH)2 vitamin 
D was unchanged in 7-month-old males (Table 1). Similarly, serum creatinine in Trpc1–/– mice was similar 
to that in WT mice at 1 year of  age (Table 1). Creatinine clearance in Trpc1–/– mice was comparable to that 
in WT mice (Table 1), indicating that renal failure could not have accounted for the hypercalcemia and 
elevated PTH levels seen in Trpc1–/– mice. Serum phosphorus levels in Trpc1–/– mice were similar to those 
in Trpc1+/+ mice (Table 1). Hematocrits were not different at 8.5 months of  age and were lower at 10.5 and 
21.5 months of  age, showing that hemoconcentration was not responsible for the hypercalcemia (Table 1). 
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Plasma levels of  calcitonin, another regulator of  serum Ca2+, were unchanged in 7-month-old Trpc1-null 
males (Table 1), suggesting that deletion of  Trpc1 does not affect calcitonin secretion from C cells of  the 
thyroid gland that could indirectly influence serum Ca2+ and/or PTH secretion.
Despite high PTH levels seen in primary hyperparathyroidism typically being associated with low bone 
mass and osteoporosis, patients with FHH manifest slightly reduced, normal, or even increased bone mass 
(20, 21). Mildly increased bone mass is also seen in mice lacking the CaSR in the PTG (22). Our previous 
work has shown that 12-week-old male Trpc1–/– mice have slightly increased bone mass (23). We extended 
the analysis to 19-month-old animals and found that Trpc1–/– mice had 83% increase in bone volume to 
tissue volume, 27% reduction in trabecular spacing, 36% increase in trabecular number and 181% increase 
in connectivity density (Supplemental Figure 2, A–D).
TRPC1 mutations not detected in patients with FHH. The phenotype of  the Trpc1–/– mice is consistent with 
that of  FHH in humans, and the possibility that mutations in the TRPC1 gene may be a cause of  hyper-
calcemia in some patients with FHH who did not have CASR, GNA11, or AP2S1 mutations was therefore 
explored. Sanger DNA sequence analysis (14 patients) or whole exome sequencing (5 patients) did not 
detect any point mutations, deletions, insertions, or unreported SNPs. However, a 16-bp segment corre-
sponding to the 5′UTR in short form of  TRPC1 or amino acid residues VGAGG in long form of  TRPC1 
(Supplemental Figure 3) could not be reliably ascertained due to repetitive elements. A binomial analysis 
predicted that the use of  19 samples in total would have a greater than 95% and 98% likelihood of  detecting 
at least 1 TRPC1 mutation, assuming a mutation prevalence of  15% and 20%, respectively (24). Whole 
exome sequencing did identify a common polymorphism (p.A14T, present in 7490 of  261,160 alleles in the 
gnomAD v2.1.1 database) in 1 patient with FHH.
Figure 1. Trpc1–/– mice exhibit hypercalcemia, hyperparathyroidism, and hypocalciuria. (A) Serum Ca2+ levels (mg/dl) 
in 7-month-old Trpc1+/+ and Trpc1–/– fasted males and females. **P < 0.01, Student’s t test. (B) Serum PTH levels (pg/
ml) in 7-month-old Trpc1+/+ and Trpc1–/– fasted males and females. *P < 0.05, Student’s t test. (C) Urine Ca2+ excretion 
(mg/day) in 7-month-old Trpc1+/+ and Trpc1–/– males and females. *P < 0.05, Student’s t test. (D) Ca2+ clearance (μl/min) 
in 7-month-old Trpc1+/+ and Trpc1–/– males and females. *P < 0.05; **P < 0.01, Student’s t test. (E) Twenty-four-hour 
urine Ca2+/creatinine ratio in 7-month-old Trpc1+/+ and Trpc1–/– males and females. *P < 0.05, Student’s t test.
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TRPC1 is required for the suppression of  PTH secretion in isolated mouse PTGs. TRPC1 was widely expressed in 
WT but not in mutant PTGs (Figure 2A). To test for a PTG-autonomous effect of  TRPC1 on PTH secretion, 
we determined the secretory capacity of  isolated PTGs from groups of  both 14-week-old male and female 
mice, as was done previously for the CaSR (22). Male and female mice had similar PTH secretion maximum 
(Rmax) and minimum (Rmin) as well as Ca2+ set points; therefore, we pooled the data to increase the power 
of  the analysis. Absolute Rmax values were approximately 3-fold higher in Trpc1–/– PTGs compared with 
those in Trpc1+/+ PTGs (Figure 2B), accompanied by a significant (P < 0.05) rightward shift in the Ca2+ set 
point from 1.04 ± 0.15 mM in Trpc1+/+ mice to 1.25 ± 0.08 mM in Trpc1–/– mice (Figure 2C). These ex vivo 
effects were more severe than the deletion of  1 allele of  Casr in the PTGs of  3-month-old mice but less severe 
than the deletion of  2 Casr alleles (22, 25), suggesting that TRPC1 may significantly contribute (by more than 
50%) to the effects of  CaSR in the secretion of  PTH from the isolated PTG.
Parathyroid cells depleted of  TRPC1 secrete more PTH. Derived from rat PTG, PTH-C1 cells express CaSR, pro-
duce and secrete PTH, and are currently the only known cell line available for studying PTH secretion in rodents 
(26). Using CRISPR/Cas9 gene editing, we introduced a frameshift in the Trpc1 locus in PTH-C1 cells and gen-
erated several stable clones. One of these clones, PTH-C1Trpc1-KO (Supplemental Figure 4, A and D), was used for 
functional PTH secretion assays. Deletion of TRPC1 led to a 44% increase in secreted PTH (from 8.7 ± 0.8 pg/
ml in WT cells to 12.6 ± 1.2 pg/ml in PTH-C1Trpc1-KO cells) in the presence of low extracellular Ca2+ concentra-
tion (0.5 mM Ca2+), which should promote PTH secretion (Figure 3A). Similar effects were seen when PTH-C1 
cells were treated with Pico145, a specific inhibitor of TRPC1/TRPC4/TRPC4 channels (27) (Supplemen-
tal Figure 5A). RT-PCR failed to detect TRPC4 or TRPC5 mRNAs in PTH-C1 cells, indicating that Pico145 
increased PTH secretion, most likely by inhibiting endogenous TRPC1 in these cells (Supplemental Figure 5B).
To examine whether endogenous TRPC1 controls PTH secretion rather than gene expression, we gener-
ated and characterized stable clones overexpressing mouse PTH using a heterologous promoter (CMV) that 
should not be affected by TRPC1 levels. Two individual clones highly expressing PTH (PTH-C1Pth-1 ~20,000-
fold and PTH-C1Pth-2 ~2,000-fold compared with parental PTH-C1 cells) were subsequently transfected with a 
TRPC1-specific CRISPR/Cas9 construct, and two individual clones (PTH-C1Pth-1/Trpc1-KO and PTH-C1Pth-2/Trpc1-
KO) with complete deletion of TRPC1 (verified by Sanger sequencing of the recombination site at the Trpc1 
locus, Supplemental Figure 4, B and C) were used for functional assays. PTH-C1Pth-1/Trpc1-KO cells secrete 50.9 
± 2.7 ng/ml PTH, which was 106% higher than that of PTH-C1Pth-1 cells (24.8 ± 2.0 ng/ml) (Figure 3B). 
Similarly, PTH-C1Pth-2/Trpc1-KO cells showed 85% higher PTH secretion (4574 ± 48 pg/ml) compared with PTH-
C1Pth-2 cells (2473 ± 53 pg/ml) (Figure 3C). Transfecting back WT TRPC1α suppressed PTH secretion by 31% 
in PTH-C1Pth-2/Trpc1-KO cells (Figure 3E). However, transfection of TRPC1α F689A, with a single amino acid 
mutation in its pore region (Figure 3D) that reduces Ca2+ permeability (28) and CaSR-induced Ca2+ influx 
(Figure 3F), failed to suppress PTH secretion (0.7%) in these cells (Figure 3E). In the presence of mutant 
Table 1. Serum and urine analysis of biochemical parameters in Trpc1+/+ and Trpc1–/– male mice
Parameter Age (mo.) Trpc1+/+ Trpc1–/– P value
Serum Mg2+ (mg %) 7 0.83 ± 0.05 (n = 16) 0.90 ± 0.03 (n = 17) NS
Serum Mg2+ (mg %) 16 0.97 ± 0.04 (n = 36) 0.90 ± 0.03 (n = 28) NS
Urine Mg2+ excretion (mg/d) 7 1.8 ± 1.4 (n = 4) 1.3 ± 2.2 (n = 6) NS
Mg2+ clearance (μl/min) 7 78 ± 3 (n = 4) 54 ± 11 (n = 6) NS
24-hour urine Mg2+/
creatinine
7 2.6 ± 0.5 (n = 4) 1.9 ± 0.3 (n = 6) NS
Serum phosphorous (mg %) 8 5.8 ± 0.3 (n = 18) 6.4 ± 0.4 (n = 14) NS
Serum 1,25 (OH)2D3 (pg/ml) 7 308 ± 8 (n = 11) 301 ± 5 (n = 14) NS
Serum calcitonin (pg/ml) 7 22.3 ± 2.6 (n = 11) 21.9 ± 2.2 (n = 14) NS
Serum creatinine (mg/dl) 12 0.074 ± 0.005 (n = 11) 0.083 ± 0.01 (n = 10) NS
24-hour urine creatinine 
clearance (ml/min/100 g 
body weight)
12 2.23 ± 0.23 (n = 11) 2.18 ± 0.29 (n = 10) NS
Hematocrit (%) 8.5 52.7 ± 1.2 (n = 12) 51.9 ± 2.3 (n = 12) NS
10.5 58.5 ± 1.3 (n = 11) 50.8 ± 1.3 (n = 5)  <0.005
21.5 56.2 ± 0.6 (n = 8) 38.4 ± 1.8 (n = 7)  <0.001
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TRPC1αF689A, spermine activation of CaSR induced less intracellular Ca2+ accumulation than PTH-C1 cells 
coexpressing CaSR and WT TRPC1α (Figure 3F). These data show that TRPC1α has an essential and specific 
role in suppressing PTH secretion in PTH-C1 cells and this property involves its ability to conduct Ca2+.
TRPC1 overexpression suppresses PTH secretion. Next, we determined whether TRPC1 overexpression 
can suppress PTH secretion in PTH-C1 cells. Overexpression of  WT TRPC1α, but not TRPC1αF689A, 
suppressed PTH secretion in PTH-C1 cells (Figure 4A). We also compared side-by-side overexpression 
of  CaSR (positive control) and 2 other highly expressed TRP channels in the PTG, TRPM4 or TRPM7 
(Figure 4B), or WT STIM1, Orai1 and their constitutively active mutants, STIM1R304W and Orai1P245L 
(29). We chose to test the effect of  WT and active mutants of  STIM1 and Orai1 on PTH secretion because 
we have previously shown that TRPC1 functions together with these proteins to increase the dynamic range 
of  SOCE channels (23). Overexpression TRPC1α or CaSR suppressed PTH secretion (Figure 4A). Overex-
pression of  TRPM4, TRPM7, STIM1, or Orai1 had no effect on PTH secretion, whereas overexpression of  
constitutively active STIM1 or Orai1 mutants increased PTH secretion. Knockdown of  Orai1 did not affect 
PTH secretion. The positive effect of  constitutively active STIM1/Orai1 mutants on PTH release is consis-
tent with the well-known role of  SOCE channels in hormonal release, exocytosis, and mast cell degranula-
tion (30). These data provided additional evidence that TRPC1 has a specific, essential, and sufficient role 
in suppressing PTH secretion in PTH-C1 cells and does so independently of  its ability to enhance SOCE.
TRPC1 functions downstream of  CaSR in PTH-C1 or HEK293 cells. To test whether TRPC1 functions 
downstream of  CaSR in Ca2+ signaling in PTH-C1 cells, we transiently depleted TRPC1 in PTH-C1 
cells using a rat Trpc1-specific siRNA. Trpc1 mRNA translation is initiated by 2 alternative start sites. 
Translation initiation by an upstream leucine generates the long form of  TRPC1, whereas initiation 
by a downstream methionine generates the short form of  TRPC1. The 2 isoforms differ by N-terminal 
extension of  78 amino acids (23). PTH-C1 cells expressed predominantly the long form of  TRPC1, 
which was downregulated in cells transfected by a rat Trpc1-specific siRNA (Figure 5A). Depletion of  
TRPC1 attenuated intracellular Ca2+ signaling in cells activated by extracellular Ca2+, spermine, or R-568 
Figure 2. Parathyroid glands lacking TRPC1 fail to properly control PTH secretion. (A) TRPC1 is widely expressed in normal 
mouse PTGs. Top: H&E staining of Trpc1+/+ (left) and Trpc1–/– (right) glands. Bottom: Expression of TRPC1 in WT (left) and 
Trpc1-null (right) PTGs by immunohistochemistry using a mouse monoclonal antibody against TRPC1 (1F1). Original mag-
nification, ×40. (B) Responses of PTH release at different [Ca2+]e (pg/30 min/gland) in PTGs isolated from 8 (3 males and 
5 females) WT and 8 (3 males and 5 females) 14-week-old Trpc1-null mice. (C) Ca2+ dose-response curves shown in B were 
normalized and are expressed as a percentage of the PTH release at 0.5 mM Ca2+. Perpendicular lines depict Ca2+ set points 
(1.04 mM ± 0.15 for Trpc1+/+ and 1.25 mM ± 0.08 for Trpc1–/– mice).
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(Figure 5, B–E), which are all well-established activators of  the CaSR (9). The response to spermine rep-
resented specific activation of  CaSR, since it was completely blocked in the presence of  the CaSR-spe-
cific inhibitor, NPS2143 (Figure 5D). These data showed that TRPC1 depletion reduced CaSR-induced 
Ca2+ signaling, consistent with the hypothesis that TRPC1 functions downstream of  CaSR activation 
to increase intracellular Ca2+ concentration to suppress PTH secretion. Activation of  CaSR can lead 
to the concurrent activation of  both SOCE and ROCE channels. Our functional PTH secretion assays 
suggested that TRPC1 functions independently of  SOCE channels in suppressing PTH secretion. Here, 
we used a heterologous system to test whether TRPC1 can be specifically coupled to CaSR and function 
independently of  SOCE channels in Ca2+ signaling. To test for the contribution of  TRPC1 in SOCE, 
HEK293 cells were transfected with TRPC1 and CaSR or m1 acetylcholine receptor (AchR), which is 
also coupled to Gα11/Gαq, and stimulated with thapsigargin to deplete internal Ca2+ stores followed by 
direct activation of  transfected CaSR or m1 AchR with spermine or carbachol, respectively. Expression 
of  TRPC1 enhanced Ca2+ signaling in cells transfected with CaSR (Figure 5F) but not m1 AchR (Figure 
5G). In addition, overexpression of  TRPC1 did not have an effect on thapsigargin-induced Ca2+ signaling. 
These data suggest that TRPC1 is coupled to CaSR via a mechanism independent of  depletion of  
intracellular Ca2+ stores, supporting our data from PTH secretion assays in PTH-C1 cells, in which over-
expression or knockdown of  STIM1 or Orai1 did not affect PTH secretion.
Gα11 physically interacts with TRPC1 and increases its activity. Given the established role of  Gα11 in 
FHH and PTH secretion (3), we asked whether Gα11 overexpression could further enhance CaSR-in-
duced TRPC1-mediated Ca2+ influx. Indeed, overexpression of  Gα11 augmented TRPC1-mediated 
Ca2+ influx in response to spermine activation of  CaSR in HEK293 cells using 2 different protocols 
(Figure 6, A and B). Gα11 could enhance TRPC1 activity by multiple mechanisms. One possible 
mechanism could involve complex formation of  Gα11 with TRPC1, as previously reported for recep-
tor-activated TRP channels and Gαq (31). Therefore, we examined whether Gα11 could interact with 
TRPC1. We tested both long and short forms of  TRPC1α and TRPC1ε isoforms. TRPC1α is the most 
widely expressed form of  TRPC1, whereas TRPC1ε has a 7–amino acid deletion at the beginning 
of  exon 5 corresponding to the N-terminal cytosolic domain of  TRPC1 and, so far, is shown to be 
Figure 3. Inactivation of the Trpc1 gene increases PTH secretion. (A–C) Absolute PTH levels in media of WT PTH-C1 
cells or cells lacking TRPC1 in the presence or absence of exogenously transfected PTH. *P < 0.05; ***P < 0.001, 
Student’s t test. (D) TRPC1 topology and location of F689. Pore-forming region connecting S5 and S6 is shown in red. 
Ankyrin repeats are shown as dark green cylinders and pre-S1 and TRP-box domains as shown are red cylinders. (E) 
Readdition of WT mouse TRPC1α but not the TRPC1αF689A pore mutant rescues suppressed PTH secretion in cells 
lacking endogenous rat TRPC1 (PTH-C1PTH-2/Trpc1-KO) cells. Data from 9–18 measurements were pooled from 3–6 indepen-
dent experiments. **P < 0.01, 1-way ANOVA. (F) Spermine-induced changes in free intracellular Ca2+ in HEK293 cells 
transiently cotransfected with CaSR plus WT TRPC1α (black, n = 296 cells pooled from 3 experiments) or TRPC1α-F689A 
(red, n = 276 cells pooled from 3 experiments).
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expressed in myeloid precursor cells (23). Coimmunoprecipitation experiments in transiently trans-
fected HEK239T cells followed by deletion analysis showed that either TRPC1α or TRPC1ε isoforms 
interacted with Gα11 through their N- and C-termini (Figure 6, C and D). Consistently, endogenous 
TRPC1 colocalized with Gα11 in PTH-C1 cells (Supplemental Figure 6). In contrast, TRPC1 did not 
interact with GαS, showing specificity of  TRPC1 to Gα11 (Figure 6, C and D). In light of  genetic data 
in which inactivating mutations in GNA11 in humans produce a phenotype also seen in Trpc1-null 
mice, plus the molecular and functional data that show that Gα11 coimmunoprecipitates and enhances 
the activity of  TRPC1, we propose that the direct interaction between TRPC1 and Gα11 potentiates 
the stimulatory effects of  CaSR on TRPC1.
Discussion
The discovery of  CaSR had a profound effect on our understanding how PTG cells sense extracellular 
Ca2+ levels (2, 6, 9, 32, 33). However, there are still gaps in our knowledge regarding how PTG cells regu-
late PTH secretion downstream of  CaSR. We provide in vivo, ex vivo, and in vitro evidence that TRPC1 
functions downstream of  CaSR to suppress PTH secretion. This information can help direct future studies 
to better our understanding of  how the Ca2+ signaling can regulate PTH release, calcitonin secretion, and 
secretion of  other hormones from cells with a functional CaSR.
Global deletion of  Trpc1 resulted in a phenotype that showed significant similarities to FHH (21, 34). 
Statistically, as a group, patients with FHH exhibit mild but significant hypercalcemia, while a few of  them 
show elevated PTH (5, 35), similar to male Trpc1–/– mice. Hypocalciuria, a hallmark of  FHH not typically 
seen in primary hyperparathyroidism (5, 36), was also observed in our Trpc1–/– mice. These data are con-
sistent with the idea that TRPC1 functions downstream of  CaSR in the PTG and the kidney. Unchanged 
1,25 (OH)2 vitamin D levels are observed in patients with FHH (34, 37, 38), which is corroborated in our 
Figure 4. TRPC1 overexpression suppresses PTH secretion independently of SOCE and other TRP channels expressed 
in the mouse PTG. (A) Normalized levels of secreted PTH in media of PTH-C1 cells transiently transfected with indi-
cated expression plasmids or siRNAs (n = 9 measurements pooled from 3 independent experiments). *P < 0.05; **P 
< 0.005; ***P < 0.001, ****P < 0.0001, 1-way ANOVA. (B) Expression levels of TRP channel mRNAs in mouse PTG by 
Affymetrix Mouse Microarray analyses. L-19 was used as the housekeeping gene (n = 4 batches of 20 PTGs).
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Trpc1–/– mice. A few differences are noteworthy between Trpc1–/– mice and patients with FHH. Serum 
Mg2+ is often moderately increased in some patients with FHH (3, 4, 39), but Mg2+ levels were normal in 
Trpc1–/– mice. Second, Trpc1–/– mice and mice with kidney-specific deletion of  Casr have normal serum 
phosphorous levels (40), unlike patients with FHH with reduced levels (35). Finally, there are changes in 
skeletal manifestation between our mice and patients with FHH. In FHH, bone mass is generally com-
parable to that of  normal controls (20, 21, 41). However, our Trpc1-null mice had substantially increased 
and progressive changes in bone mass with age. Indeed, previously we reported significantly decreased 
osteoblast number per bone surface and reduced osteoclast numbers per bone surface in histomorphometric 
assays of  3-month-old Trpc1-null mice (23). These similarities and differences may correlate to compensa-
tory proteins that differ between mice and humans in the kidney, PTG, and bone cells. With the exception 
of  Casr+/– mice (42) and a newly described mouse model carrying a loss-of-function mutation (D195G) in 
Figure 5. TRPC1 is required for CaSR-induced Ca2+ signaling in PTH-C1 cells. (A) Efficiency of TRPC1 knockdown using 
RNAi. PTH-C1 cells were transiently transfected with a scrambled siRNA (lane 1), siTRPC1 (lane 2), expression plasmid 
(positive control) of a long form of TRPC1α (lane 3), or a short form of TRPC1α (lane 4). TRPC1 was immunoprecipitated 
and immunoblotted with a TRPC1-specific monoclonal antibody (1F1). PTH-C1 cells express predominantly the long 
form of TRPC1α (indicated by an asterisk). (B) Changes in intracellular Ca2+ concentration (expressed as fluorescence 
ratio 340/380) in PTH-C1 cells transiently transfected with a scrambled siRNA (control, black, n = 76 cells pooled from 5 
independent experiments) or a Trpc1-specific siRNA (siTRPC1, red, n = 61 cells pooled from 6 independent experiments) 
and cultured in 1, 5, or 10 mM extracellular Ca2+. (C) Time course of spermine-induced (5 mM) intracellular Ca2+ concen-
tration in PTH-C1 cells transiently transfected with a scrambled siRNA (control, black, n = 144 cells pooled from 4 inde-
pendent experiments) or a Trpc1-specific siRNA (siTRPC1, red, n = 178 cells pooled from 8 independent experiments). (D) 
Time course of intracellular Ca2+ concentration in PTH-C1 cells cultured in 0 extracellular Ca2+ and activated by spermine 
(3 mM) in the presence (blue, n = 279 cells from 6 experiments) or absence of NPS2143 (300 nM) (black, n = 233 cells 
from 5 experiments). (E) Time course of R568-induced (50 μM) intracellular Ca2+ concentration in PTH-C1 cells tran-
siently cotransfected with GCaMP3 and scrambled siRNA (control, black line, n = 216 cells pooled from 9 independent 
experiments) or TRPC1 siRNA (siTRPC1, red line, n = 172 cells pooled from 9 independent experiments) in the presence 
of 1.8 mM extracellular Ca2+ concentration. F0 was the average fluorescence for 1 minute prior to the addition of R-568. 
(F and G) TRPC1 is specifically coupled to CaSR. HEK293 cells were transiently cotransfected with GCaMP3, CaSR (F), or 
m1 muscarinic acetylcholine receptor (m1 AchR, G) in the presence or absence of TRPC1 (red or black traces). Cells were 
first stimulated with thapsigargin (2 μM) to deplete the internal stores and then with spermine (2 mM, F) or carbachol 
(10 μM, G) to activate CaSR or m1 AchR, respectively. Changes in intracellular free Ca2+ concentration are reported as F/
F0. Data were pooled from 6 independent experiments totaling 263 cells transfected with CaSR (black, F) and 316 cells 
transfected with CaSR plus TRPC1 (red, F) or from 8 independent experiments totaling 190 cells transfected with m1 
AchR (black, G) and 173 cells transfected with m1 AchR plus TRPC1 (red, G).
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Figure 6. Gα11 physically interacts with TRPC1 and increases its activity. (A and B) Gα11 increases TRPC1-mediated Ca2+ signaling in HEK293 cells. Cells 
were transiently transfected with CaSR and TRPC1α or CaSR, TRPC1α, and Gα11. Both groups were cotransfected with the fluorescent Ca2+ indicator, 
GCaMP3, and fluorescence intensity was determined by single-cell Ca2+ imaging. Changes in intracellular Ca2+ concentration (F/F0) in response to spermine 
(1 mM) were determined under physiological conditions (1.8 mM extracellular Ca2+, A) or in Ca2+-free ECS followed by Ca2+ readdition (2 mM, B). Data were 
pooled from 74 (black) or 85 (red) cells from 2 independent transfections (A) and 318 (black) or 261 (red) cells from 4 independent transfections (B). (C) 
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Gna11 (43), which recapitulates human FHH both at the disease phenotypic and genetic levels, there are no 
other suitable mouse models for FHH, including orthologous mouse models. For example, while dominant 
loss-of-function mutations in GNA11 result in FHH in patients (3), homozygous global deletion of  Gna11 
in the mouse did not produce a significant phenotype (44). The PTG-specific deletion of  Gnaq combined 
with global deletion of  Gna11 recapitulated some aspects of  FHH in the mouse (45), suggesting potential 
gene redundancy by Gnaq in the mouse but not in humans. Alternatively, dominant negative effects of  loss-
of-function alleles of  Gna11 could be implicated in FHH. Nevertheless, the generation of  additional mouse 
models of  FHH could help advance our understanding of  the pathophysiology of  FHH and diseases of  
the PTG. We believe that the global Trpc1-KO mouse model presented here can be considered as a suitable 
mouse model for FHH because it recapitulates several key features of  FHH. Additional refinements could 
be made by the tissue-specific deletion of  Trpc1 in the PTG, bone, and kidney.
Our data suggest that Gα11-mediated signaling downstream of  CaSR couples serum Ca2+ concentra-
tion and PTH secretion. CaSR is linked to several classes of  Gα subunits and it remains unknown which 
subclass(es) and how specific G protein(s) mediate the CaSR’s effects on PTH secretion (9). The identifica-
tion of  naturally occurring mutations in GNA11 in patients with FHH2 strongly suggests that the Gα11/αq 
subclass conveys the signal to suppress PTH secretion following activation of  CaSR (3). Our data support 
this hypothesis and further identify the ion channel mediating such an effect. While we favor the idea that 
TRPC1 is a direct target of  activated Gα11, we cannot rule out a possible modulation of  TRPC1 activity 
by other Gα subclasses coupled to CaSR, either directly via protein-protein interactions or indirectly via 
cAMP/PKA-mediated signaling (Gαi/o) and regulation of  the actin cytoskeleton (Gα12/13). The FHH-
like phenotype we observed in Trpc1-null mice is less severe than the phenotype produced by the deletion 
of  CaSR in mice (22, 42), suggesting that loss of  TRPC1 in the PTG produces a milder phenotype than 
the loss of  CaSR signaling. While other Gα11-activated Ca2+-permeable channels can work in parallel with 
TRPC1 to suppress PTH secretion, Ca2+-independent signaling could also account for the remaining effect 
of  PTH suppression in Trpc1-null cells/tissues. Alternatively, TRPC1-mediated Ca2+ signaling may have a 
permissive role in the suppression of  PTH secretion under conditions of  abnormally high serum Ca2+ lev-
els. Regardless of  the exact mechanism by which TRPC1 influences PTH secretion and the extent to which 
it contributes to the overall effect of  CaSR on PTH secretion, our studies identify what is probably the first 
ion channel that can function downstream of  CaSR in the control of  PTH secretion and, thus, can spur 
new studies on the role of  Ca2+ signaling in PTH homeostasis.
While TRPC1 was the first mammalian TRP channel identified more than 20 years ago (46), its activa-
tion mechanism remains unclear (13). Our studies identifying TRPC1 as part of  the cellular apparatus con-
trolling PTH secretion have implications in its activation mechanisms. We had shown earlier that TRPC1 
can be activated by store depletion (23), but our PTH secretion data in PTH-C1 cells show that activation 
by store depletion could not account for its effect on PTH secretion. This conclusion is based on PTH secre-
tion data, whereby overexpression or depletion of  STIM1 or Orai1 did not affect PTH secretion in PTH-C1 
cells and, furthermore, overexpression of  constitutively active STIM1 and Orai1 identified in patients with 
Stormorken or a Stormorken-like syndrome, respectively, enhanced rather than suppressed PTH secretion. 
While this seems to be at odds with mild hypocalcemia reported in some patients with Stormorken (47), it 
is in agreement with the well-established role of  SOCE channels in exocytosis and hormonal release (30). 
The hypocalcemia seen in patients with Stormorken could be due to secondary effects of  STIM1R304W in 
tissues other than the PTG, such as the kidney or bone. More studies are necessary to determine the effect 
of  STIM1R304W or Orai1P245L on hypocalcemia.
We show that overexpression of  Gα11 increases TRPC1-mediated Ca2+ influx and Gα11 physically 
interacts with both the N- and C-terminus of  TRPC1. We propose that TRPC1 can be directly activated by 
a physical interaction with Gα11. Our data do not favor the idea that freed Gβγ complex mediates an effect 
HEK293T cells were transiently transfected with the long form of TRPC1ε, short form of TRPC1ε, short form of TRPC1α, long form of TRPC1α, or the same 
TRPC1 plasmids plus myc-tagged Gα11 (top 3 rows) or GαS (bottom 3 rows). Gα11 was immunoprecipitated using α-myc, and GαS was immunoprecipitated 
using α-GαS. TRPC1 was detected in the complexes using anti-TRPC1 (top). TRPC1 input is shown in middle panels, and immunoprecipitated Gα11 or GαS 
is shown in bottom panels. (D) Truncation mutants of TRPC1α (GST alone, GST-N(α)-ter, GST-N(ε)-ter, GST-ΔNΔC, GST-C-ter, GST-ΔN) shown in E tagged 
with GST (blue cylinders) were cotransfected with WT Gα11 or GαS. Protein-protein interactions were determined by GST pulldowns followed by immuno-
blotting. Gα11 (first panel), but not GαS (third panel), interacted with the cytosolic N- or C-tail of TRPC1. Gα11 input is shown in second panel, GαS input is 
shown in fourth panel, and immunoprecipitated mutants of TRPC1 are shown.
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on TRPC1, because inhibition of  Gβγ complex with Gallein did not affect PTH secretion in PTH-C1 cells 
(our unpublished observations). Direct Gαq-mediated regulation of  TRP channels was first described in the 
Drosophila TRPL channel (31), which shows the closest homology to members of  the TRPC subgroup of  
mammalian TRP channels. Recently, TRPC4 or TRPC5 was shown to physically interact with Gαq, which 
is structurally related to Gα11 (48). We have shown that TRP channels, including the canonical group 
(TRPC1-7), require an intramolecular interaction between their N- and C-termini during activation (49). 
This intramolecular interaction is influenced by levels of  membrane phospholipid, PIP2, and mediated by 
a tryptophan residue in the pre-S1 domain and an arginine residue in the TRP-box domain in the C-termi-
nal tail. It would be interesting to know whether interaction of  TRCP1 and Gα11 involves these domains. 
Nevertheless, because Gα11 interacted with both the N- and C-terminus of  TRPC1 and overexpression of  
Gα11 increased TRPC1 activity, we speculated that a physical interaction with Gα11, following PIP2 break-
down would stabilize the N-/C-interaction causing faster activation of  TRPC1.
In summary, our data identify TRPC1 as one of  the channels mediating a critical step in the suppres-
sion of  PTH secretion in response to a rise in serum Ca2+. Information generated by our studies could be 
useful in designing new and more effective therapeutic approaches for diseases of  the PTG by targeting 
molecules downstream of  CaSR.
Methods
Mice
Mice were maintained under pathogen-free condition in the barrier facility of  University of  Oklahoma 
Health Sciences Center. WT (Trpc1+/+) and Trpc1−/− mice were on a pure 129/SvEv background (19).
Cell culture
PTH-C1 cells, a cell line derived from rat PTG, were a gift from Maria Luisa Brandi (FirmoLab, Università deg-
li Studi di Firenze) and cultured in prescribed conditions (26). HEK293 and HEK293T cells were purchased 
from ATCC and cultured in DMEM (Corning; 10-013) enriched by 10% FBS (Atlanta Biologicals; S11550).
In vivo studies
Collection of  blood, urine, and clearance samples. Mice were weighed every 7–10 days. Studies were performed 
on mutant (Trpc1–/–) and littermate controls (Trpc1+/+) from 3.5 to 21.5 months of  age. Twenty-four-hour 
urine was collected at various times over 21.5 months in individual metabolic cages. A trace amount of  sug-
ar was added to drinking water to promote ingestion and to increase urine volume in order to optimize the 
completeness of  collection, as verified by daily creatinine excretion. Water and food intake was monitored 
during the balance studies. Blood was collected by tail bleed, fasted or unfasted, whichever appropriate, 
periodically from age 7 to 21.5 months, usually synchronized with metabolic urine collections, as appro-
priate. Renal clearance was performed in individual mice at 21.5 months to measure Ca2+ in urine directly 
collected from urinary bladder via indwelling catheters and to measure glomerular filtration rate by intrave-
nously infused inulin using methods we established, as described earlier (50).
Measurements of creatinine, Ca2+, and Mg2+ in urine and blood and analysis of blood PTH, 
calcitriol, and calcitonin
Creatinine was measured by HPLC (Buck Scientific). Ca2+ was measured using Ca Arsenazo III dye 
adapted for a plate reader (Pointe Scientific). Mg2+ was measured using Arsenazo dye (Thermo Scien-
tific Fisher). PTH was measured using a Mouse PTH 1-84 ELISA kit (Immunotopics). Mouse calcitriol 
(or 1,25-dihydroxyvitamin D) and calcitonin were measured using ELISA kits (Mybiosource, catalog 
MBS816417 and MBS026850, respectively).
RNA interference
PTH-C1 cells were cultured to 70% confluency and transfected with siTRPC1 (Dharmacon; L-080128-
02-0005) or siOrai1 (Dharmacon; L-081151-02-0005) or nontargeting siRNA (Dharmacon; D-001810-10-
05) using Lipofectamine3000 (Invitrogen). Two days after transfection, cells were transferred into 24-well 
plates for PTH secretion analysis or 18-mm glass disks for single-cell Ca2+ imaging analysis.
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CRISPR/Cas9
Exon 1 of  the rat Trpc1 locus was edited using CRISPR/Cas9 and the following guide: (T2) 5′-CAC-
CGGGCGCTGAAGGATGTGCGAG-3′ or (T3) 5′-CACCGGGCGGCCCTGTACCCGAGCA-3′. The 
Trpc1-specific sgRNA (T2) was cloned into lentiCRISPRv2 puro vector (Addgene) and used to transfect 
PTH-C1 cells. Puromycin-resistant stable clones were obtained and expanded, and gene editing of  the 
Trpc1 locus was determined by Sanger sequencing.
Patients and DNA sequence analysis
Nineteen unrelated patients with FHH in whom previous mutational analysis of CASR, GNA11, and AP2S1 
genes by Sanger DNA sequencing had not identified any abnormalities of the coding regions and exon-intron 
boundaries, were analyzed. DNA sequence analyses, using Sanger sequencing, of TRPC1 exons 1–12 of tran-
script ENST00000273482 and their adjacent splice sites were performed using leucocyte DNA and gene-spe-
cific primers (MilliporeSigma) (Supplemental Table 1), as previously reported (24). WES was performed using 
leucocyte DNA, as previously described (4). Publicly accessible databases were examined for the presence of  
sequence variants, including dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/); 1000 genomes (https://
www.internationalgenome.org/home); the National Heart, Lung and Blood Institute Exome Sequencing Proj-
ect (http://evs.gs.washington.edu/EVS/, EVS data release ESP6500SI), representing the exomes of approxi-
mately 6500 individuals; and the gnomAD v2.1.1 database (https://gnomad.broadinstitute.org/), representing 
125,748 exomes and 15,708 genomes of unrelated individuals mapped to the GRCh37/hg19 reference sequence.
Expression plasmids
Mouse PTH (MR200486) and Gnα11 (MR205495) cDNAs were purchased from Origene. Human Orai1 
(BC015369), mouse STIM1 (BC021644), and mouse TRPC1α or TRPC1ε (CA327829) were obtained from 
Open Biosystems, as described earlier (23). TRPM4 and TRPM7 cDNAs were obtained from A. Scharen-
berg (University of  Washington, Seattle, Washington, USA).
Single cell Ca2+ imaging
Fura2/AM labeling. PTH-C1 cells were plated onto glass coverslips and loaded with 2 μM Fura-2/AM in 
extracellular solution (ECS) containing 140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 10 mM glu-
cose, and 15 mM HEPES, pH 7.4 ([Ca2+]o: 1.8 mM) in the presence of  0.05% Pluronic F-127 (ThermoFisher 
catalog P3000MP) for 45 minutes at room temperature. Cells were washed twice in ECS and incubated for 
15 minutes in 37°C before intracellular imaging. Cells were incubated in ECS (Figure 5, B and C) or a Ca2+-
free solution (same as ECS but without CaCl2) (Figure 5D) and stimulated with extracellular Ca
2+ (Figure 
5B) or spermine (Figure 5, C and D) at the indicated times. Individual cells were excited by the DeltaRam X 
monochromator (Photon Technology International), and emission images were collected by a high-definition 
imaging scientific CMOS camera driven by the EasyRatioPro software (Photon Technology International). 
Fluorescence ratios of  340/380 were taken every 5 seconds using a 30-millisecond exposure time. Intracellu-
lar Ca2+ concentration was expressed as 340/380 ratio.
GCaMP3 labeling. PTH-C1 (Figure 6E) or HEK293 cells (Figure 3F; Figure 5, F and G; and Figure 
6, A and B) were transfected with GFP-based calcium sensor for imaging calcium dynamics (GCaMP3). 
GCaMP3 was a gift from Loren Looger (Addgene plasmid, catalog 22692). Two days after transfection, cells 
were processed for single-cell Ca2+ imaging as described for Fura2/AM-labeled cells, but excitation was set at 
474 nm and emission at 510 nm. Fluorescence intensity was acquired every 5 seconds for 100 milliseconds, 
and intracellular Ca2+ concentration was expressed as the ratio of  fluorescence signal at any given time point 
over baseline fluorescence (F0, average fluorescence intensity before the addition of  drug) (F/F0).
Ex vivo secretion of PTH
Sixteen-week-old mice were euthanized and PTGs were extracted. PTH secretion was performed as pre-
viously described (23). Glands were immediately transferred into 500 μl inhibition buffer solution (3 mM 
Ca2+, 0.5 mM Mg2+, 0.2% BSA, 20 mM HEPES/MEM-EBSS-CMF, pH 7.4) and kept on ice. Next, glands 
were transferred onto 0.1 μM Nucleopore Track-Etch Membrane (Whatman; 110405) and equilibrated in 
inhibition solution for 1 hour in a 37°C/5% CO2 incubator. Membranes with glands were transferred in 
buffer solutions (500 μl) containing 0.5, 0.75, 1, 1.25, 1.5, 2, or 3 mM Ca2+ for 30 minutes. Secreted PTH 
was determined using the Mouse PTH 1-84 ELISA Kit (Immutopics; 60-2305).
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In vitro secretion of PTH
Secreted PTH from native and transiently or stably transfected PTH-C1 cells was determined using a Rat 
Intact PTH ELISA Kit (Immutopics; 60-2500). PTH was collected after 4-hour incubation in fresh secre-
tion media solution (0.5 mM Ca2+, 0.5 mM Mg2+, 0.2% BSA, 20 mM HEPES/MEM-EBSS-CMF, pH 7.4) 
prior to quantification of  PTH.
PCR
PTH-C1 cells were collected in TRIzol (Invitrogen; 15596026). RNA isolation was performed according to the 
manufacturer’s instructions. Five μg RNA was used for reverse transcription. mRNA was combined with oligo 
(dT) 12-18 primer (Invitrogen; 18418012) and random hexamers (Invitrogen; N8080127) and incubated for 10 
minutes in 70°C. Next, 5× buffer, 0.5 μM dNTP, 10 mM DTT, and 20 U/μl SuperScript III were added (reverse 
transcription kit 18080093 from Invitrogen) and reaction was performed under the following conditions: 42°C 
for 45 minutes, 52°C for 30 minutes, and 70°C for 15 minutes. Primers used for further PCR were as follows: 
TRPC1 forward, GAGTTACCTTCGGCTCTTCTTT, reverse, GCTGAGGCTGCTGATCATATAG; nested 
forward, GCTCTGTTCTGGTACATCTTCTC, reverse, GGCAGTGTGCATTTGTCATC; TRPC4 forward, 
GAATGCTCCTGGACATCCTAAA, reverse, CCTCATCACCTCTTGGTATTGG; nested forward, GGT-
TAAGCTGCAAAGGCATAC, reverse, CCAAAGCTTTCTGGCTTTCTTC; TRPC5 forward, CAAG-
GTCCCGACTGAACATATAC, reverse, GCATGAAGAGGAAGGTCAGATAG; and nested forward, 
CTTCGCTCATCGCCTTATCA, reverse, ATGCTGTGTGGCAGATGAA.
Affymetrix Mouse Microarray analyses
For RNA expression in mouse PTGs, 4 batches of  glands (PTGs) were dissected free of  thyroid and the 
surrounding fibrous tissues and used for RNA extraction with a RNA-Stat 60 kit (Thermo Fisher Scientific) 
as described previously (25). The RNA was reversed transcribed into cDNA, which was then subjected to 
Affymetrix Mouse GeneChip Microarray analyses by the Genome Technologies Core Facility (University 
of  Manchester) and Genome Analyses Microarray Core (University of  California, San Francisco). The 
gene array data were analyzed using Affymetrix Genechip Software for an intensity value and normalized 
and presented as a percentage of  the expression level of  a mitochondrial microsomal protein L19 and used 
for statistical analyses (n = 4 batches of  RNA with each batch extracted from 20 PTGs dissected from 10 
of  6-week-old C57bB6 mice).
Coimmunoprecipitation
PTH-C1 or HEK293T cells were lysed in native lysis solution (1% Triton X-100, 150 mM NaCl, 10 mM 
Tris-HCl, pH. 7.5, 1 mM EDTA, 1 mM EGTA, 0.5% Igepal, 10 % sucrose, 5 mM NaF, 200 μM vanadate, 
protease inhibitor) in 4°C for 30 minutes. Cleared lysates were collected and used for coimmunoprecip-
itations. Myc- or GST-tagged proteins were captured using a rabbit monoclonal antibody against myc 
tag (clone 71D10, Cell Signaling; 2278) or Glutathione Sepharose 4B (GE Healthcare; GE17-0756-01), 
respectively. TRPC1 was detected using 1F1 (51), GαS (Santa Cruz; sc-135914), or GST (Santa Cruz; 
sc-459). Gα11 was detected using FLAG antibody (clone M2, MilliporeSigma; F1804).
Immunohistochemistry staining for mouse PTG
Four-micron-thick histological sections, embedded in paraffin and mounted on HistoBond Plus slides (Stat-
lab Medical Products), were rehydrated and washed in Tris-buffered saline. The sections were processed 
for immunohistochemistry using M.O.M. (Mouse on Mouse ImmPRESS Peroxidase Polymer kit, Vector 
Labs) or, for rabbit antibodies, the ImmPRESS –VR Horse Anti-Rabbit IgG Polymer Peroxidase kit (Vector 
Labs). Antigen retrieval (pH 6 Citrate Antigen Unmasking Solution, Vector Labs) was accomplished via 
20 minutes in a steamer followed by 30 minutes cooling at room temperature. Sections were treated with a 
peroxidase blocking reagent (Bloxall, Vector Laboratories)
Double indirect immunofluorescence labeling
PTH-C1 and PTH-C1Trpc1-KO cells seeded on coverslips were fixed with cold methanol for 5 minutes in 
room temperature and then washed 3 times with ice-cold PBS. Cells were permeabilized with 0.5% Sapo-
nin solution for 10 minutes followed by 3 washes in PBS. Blocking was done with 3% BSA for 15 min-
utes, and then cells were incubated with primary antibody (TRPC1-1F1, 1:500, Gα11 1:200) diluted in 
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1% BSA in 4° C overnight. Secondary antibodies coupled to Alexa Fluor 488 (Thermo Scientific Fisher; 
A11029, used at 1:2,000 dilution) or Alexa Fluor 594 (Thermo Scientific Fisher; A11012, used at 1:2,000 
dilution) were added on coverslips for 2 hours at 4°C followed by 3 washes in PBS. Coverslips were 
mounted with Diamond DAPI solution (ProLong Diamond Antifade Mountant with DAPI, Thermo 
Scientific Fisher; P36962). Images were acquired and processed with laser scanning confocal microscope 
(Olympus Fluoview 1000) in an inverted configuration.
Statistics
All experiments showing protein-protein interactions and indirect immunofluorescence staining were 
repeated at least 3 times. Data measurements were presented as mean value ± SEM. Differences between 
2 groups were determined by unpaired, 2-tailed Student’s t test or Mann Whitney test (if  data within 
groups fail to show normal distribution as determined by the D’Agostino-Pearson normality test). Sig-
nificant differences between more than 2 groups were determined by 1- or 2-way ANOVA, as indicated 
followed by Sidak’s multiple comparison test or Kruskal-Wallis test followed by Dunn’s multiple compar-
ison test (if  data failed the D’Agostino & Pearson normality test). All statistical analyses were performed 
using GraphPad Prism 7 software. P values of  less than 0.05 were considered significant.
To establish whether our analysis was sufficiently powered to detect at least 1 TRPC1 mutation with a 
greater than 95% likelihood, the sample size required was determined by binomial probability analysis (Mic-
rosoft Excel), as previously reported (24). Approximately 65% of patients with FHH1 have a CASR mutation 
(52), and for this binomial analysis the prevalence for TRPC1 mutations in patients with FHH without CASR, 
GNA11, or AP2S1 mutations was set at 20%, and a similar approach to that described for a search of  AP2S1 
mutations in ADH patients was used (24). The binomial distribution probability was calculated using the 
following formula: binomial distribution probability = b(x;n,p), where b(x;n,p) = (nx)px(1−p)n−x, where n 
indicates sample size, x represents the number of  probands harboring mutations; n–x denotes the number of  
probands with no mutation; and p represents the prevalence of  TRPC1 mutations in the cohort.
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